Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Baseline characteristics between the hypocalcemia and non-hypocalcemia group. Summary of the Parameters | Incidence of any grade hypocalcemia (n = 9) | No incidence of hypocalcemia (n = 26) | p-value: 25(OH)D (ng/mL) | 13.8 (9.4/13.8) | 12.5 (10.4/16.1) | 0.829
Source: Results table. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Thirty-five patients were included in the study, with 30 completing 3 mo of follow-up.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Bone turnover markers as predictors of hypocalcemia in patients with bone metastases receiving denosumab
Study design awaiting verification · JBMR Plus · 2025
Original publication title
Bone turnover markers as predictors of hypocalcemia in patients with bone metastases receiving denosumab
© The Author(s) 2025. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Abstract
Denosumab treatment is effective for the prevention of skeletal-related events in patients with bone metastases. However, hypocalcemia has been recognized as a serious adverse effect of denosumab. This study aimed to identify the risk factors for hypocalcemia in patients with bone metastases. In this prospective open-label study, 35 patients with bone metastases to be treated with denosumab were recruited. During the 3 months follow-up, 9 patients (25.7%) experienced hypocalcemia. Higher bone turnover status at baseline was observed in patients with hypocalcemia than in those without hypocalcemia following denosumab administration (total-P1NP, TRACP-5b, and S-NTX: all p < .05).
Negative correlations were observed between the lowest calcium levels and baseline bone turnover markers (BTMs) levels (total-P1NP: r = −0.3987; TRACP-5b: r = −0.3664; S-NTX: r = −0.3672, all p < .05). Multivariate logistic regression analysis revealed that patients with high BTMs (BAP > 32.1 μg/L, total P1NP > 82.3 μg/L, TRACP-5b > 866 mU/dL, S-NTX > 30.8 nmol BCE/L) had a higher risk of hypocalcemia, even after adjusting for reported risk factors, such as age, baseline calcium levels, and renal function (BAP > 32.1 μg/L: OR = 10.4; total P1NP > 82.3 μg/L: OR = 22.07; TRACP-5b > 866 mU/dL: OR = 36.5; S-NTX > 30.8 nmol BCE/L: OR = 39.74, all p < .05).
This study shows that denosumab significantly affects serum calcium levels in patients with bone metastases who have high bone turnover status. Bone turnover markers could serve as surrogate markers to predict hypocalcemia.
Authors’ abstract
Abstract
Denosumab treatment is effective for the prevention of skeletal-related events in patients with bone metastases. However, hypocalcemia has been recognized as a serious adverse effect of denosumab. This study aimed to identify the risk factors for hypocalcemia in patients with bone metastases. In this prospective open-label study, 35 patients with bone metastases to be treated with denosumab were recruited. During the 3 months follow-up, 9 patients (25.7%) experienced hypocalcemia. Higher bone turnover status at baseline was observed in patients with hypocalcemia than in those without hypocalcemia following denosumab administration (total-P1NP, TRACP-5b, and S-NTX: all p < .05).
Negative correlations were observed between the lowest calcium levels and baseline bone turnover markers (BTMs) levels (total-P1NP: r = −0.3987; TRACP-5b: r = −0.3664; S-NTX: r = −0.3672, all p < .05). Multivariate logistic regression analysis revealed that patients with high BTMs (BAP > 32.1 μg/L, total P1NP > 82.3 μg/L, TRACP-5b > 866 mU/dL, S-NTX > 30.8 nmol BCE/L) had a higher risk of hypocalcemia, even after adjusting for reported risk factors, such as age, baseline calcium levels, and renal function (BAP > 32.1 μg/L: OR = 10.4; total P1NP > 82.3 μg/L: OR = 22.07; TRACP-5b > 866 mU/dL: OR = 36.5; S-NTX > 30.8 nmol BCE/L: OR = 39.74, all p < .05).
This study shows that denosumab significantly affects serum calcium levels in patients with bone metastases who have high bone turnover status. Bone turnover markers could serve as surrogate markers to predict hypocalcemia.
Publication and source details
Original title: Bone turnover markers as predictors of hypocalcemia in patients with bone metastases receiving denosumab
Koki Tsuchiya; Yusuke Oshita; Haruka Emori; Soji Tani; Takashi Nagai; Austin Ennis; Mahoko Ishikawa; Yoshifumi Kudo; Benjamin Alman; Koji Ishikawa
JBMR Plus · 2025
Corresponding author: Koji Ishikawa, Department of Orthopaedic Surgery, Duke University School of Medicine, 308 Research Drive, Durham, NC, 27710, United States. (koji.ishikawa@duke.edu)© The Author(s) 2025. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.2025https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Fostering Joint International Research (A) 22KK0265 Japan Society for the Promotion of Science (JSPS) KAKENHIRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T07:05:03.488634+00:00
DOI: 10.1093/jbmrpl/ziaf013 · PMC11911062